{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:15:05Z","timestamp":1792800905585,"version":"4.5.0"},"reference-count":5,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,30]]},"abstract":"<jats:p>We describe a patient who developed a cutaneous sarcoidosis-like reaction while on pembrolizumab, with both a facial lupus pernio-like rash and large subcutaneous nodules (Darier-Roussy disease) on her limbs.<\/jats:p>","DOI":"10.1093\/skinhd\/vzag114","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T16:16:31Z","timestamp":1784909791000},"page":"821-822","source":"Crossref","is-referenced-by-count":1,"title":["Polymorphous immunotherapy-induced cutaneous sarcoidosis"],"prefix":"10.1093","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-3592-4373","authenticated-orcid":false,"given":"Lucy","family":"Mackie","sequence":"first","affiliation":[{"name":"Department of Dermatology, St George\u2019s University Hospital , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Terlizzo","sequence":"additional","affiliation":[{"name":"Department of Pathology, Royal Marsden Hospital , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolo","family":"Battisti","sequence":"additional","affiliation":[{"name":"Department of Oncology, Royal Marsden Hospital , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara","family":"Heelan","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Royal Marsden Hospital , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Aguilar-Duran","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Royal Marsden Hospital , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"2026092919515462100_vzag114-B1","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16020340","article-title":"Incidence of cutaneous immune-related adverse events and outcomes in immune checkpoint inhibitor-containing regimens: a systematic review and meta-analysis","volume":"16","author":"Curkovic","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2026092919515462100_vzag114-B2","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2022-252766","article-title":"Immunotherapy-induced exclusively cutaneous sarcoid-like reaction","volume":"16","author":"Mazumder","year":"2023","journal-title":"BMJ Case Rep"},{"key":"2026092919515462100_vzag114-B3","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1001\/jamadermatol.2018.1912","article-title":"Timing of onset of adverse cutaneous reactions associated with programmed cell death protein 1 inhibitor therapy","volume":"154","author":"Wang","year":"2018","journal-title":"JAMA Dermatol"},{"key":"2026092919515462100_vzag114-B4","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/CMR.0000000000000437","article-title":"Sarcoid-like reactions in patients receiving modern melanoma treatment","volume":"28","author":"Dimitriou","year":"2018","journal-title":"Melanoma Res"},{"key":"2026092919515462100_vzag114-B5","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/DAD.0000000000001066","article-title":"Granulomatous tumoral melanosis associated with pembrolizumab therapy: a mimicker of disease progression in metastatic melanoma","volume":"40","author":"Woodbeck","year":"2018","journal-title":"Am J Dermatopathol"}],"container-title":["Skin Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/6\/5\/821\/69955667\/vzag114.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/6\/5\/821\/69955667\/vzag114.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:51:57Z","timestamp":1790725917000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/skinhd\/article\/6\/5\/821\/8741500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":5,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,7,24]]},"published-print":{"date-parts":[[2026,9,30]]}},"URL":"https:\/\/doi.org\/10.1093\/skinhd\/vzag114","relation":{},"ISSN":["2690-442X"],"issn-type":[{"value":"2690-442X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,7,24]]}}}